Physician profile
Vinay Mulkanoor
NPI 1457793150
$781.86
in general payments reported to CMS, 2019-2025
17 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.73 · 2020: $21.45 · 2021: $54.84 · 2022: $58.65 · 2023: $6.16 · 2024: $117 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499 · Education: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.42 |
| Education | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $248.30 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $89.23 | 2021-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $72.85 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $55.26 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $49.43 | 2022-2025 | Lupkynis |
| Travere Therapeutics, INC. | $42.15 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $31.86 | 2019-2024 | Lokelma |
| Cycle Pharmaceuticals INC | $24.33 | 2025 | Venxxiva |
| Novo Nordisk INC | $24.12 | 2025 | Ozempic |
| Mannkind Corporation | $23.25 | 2025 | |
| Calliditas Therapeutics US INC. | $22.95 | 2025 | Tarpeyo |
| Apellis Pharmaceuticals, INC. | $22.75 | 2025 | |
| Ardelyx, INC. | $19.60 | 2024 | Ibsrela |
| Nxstage Medical, INC. | $17.74 | 2019 | |
| Opko Pharmaceuticals, LLC | $16.62 | 2025 | Rayaldee |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.36 | 2025 | Ultomiris |
| Akebia Therapeutics INC | $5.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Mulkanoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.